REGN
The headline nobody wanted
Regeneron disclosed on May 16 that its Phase 3 melanoma study for fianlimab plus Libtayo (cemiplimab) failed to meet its primary endpoint versus Keytruda. In biotech, that’s the kind of news that can turn a promising growth story into a very expensive science project.
Why the market cared
The stock opened down more than 10%, which is basically Wall Street’s version of tossing a chair across the room. Investors had been leaning on the combo as a meaningful pipeline catalyst, so a miss here doesn’t just bruise sentiment — it raises the “what’s next?” question for the whole oncology narrative.
The legal plot twist
The article is framed as an investigation notice from Levi & Korsinsky, but the real moving part for investors is the trial failure itself. These kinds of post-drop investigations often show up after a sharp selloff, which means more headline risk could be lurking in the background.
Big picture
For now, the takeaway is simple: one bad trial readout can yank a biotech stock around faster than a toddler on a sugar high. Regeneron still has a big platform and other shots on goal, but this is one of those moments where the pipeline story gets a little less glossy.